NY-PVH/TOMMY
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], announces the six finalists in the 2019 Tommy Hilfiger Fashion Frontier Challenge. Now in its second year, the global program aims to support entrepreneurial start-up and scale-up businesses developing solutions that promote inclusive and positive change in fashion. The selection of finalists is a next step in the journey to identify and champion innovative opportunities that support the advancement of the industry. On February 13, 2020, the six finalists will visit Tommy Hilfiger’s Campus of the Future in Amsterdam, the Netherlands, to pitch their business concepts to a jury of internal and external business and sustainability leaders at the global Tommy Hilfiger Fashion Frontier Challenge Final Event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200112005011/en/
“It is inspiring to see the second edition of the Tommy Hilfiger Fashion Frontier Challenge draw so many applicants working towards a more inclusive and sustainable fashion landscape,” said Tommy Hilfiger. “We are committed to championing bright, innovative solutions to some of our industry’s big challenges, and I’m looking forward to returning as a jury member to recognize this year’s entrepreneurs. Their shared optimism and commitment to a positive future should inspire us all in the impact we can make together.”
Over a multi-step four-month process, over 420 applicants were narrowed down to six finalists who were invited to develop and refine their business plans with the support of a dedicated team of social entrepreneur experts at the Campus of the Future. The finalists include:
- Bangladesh-based scale-up, Apon Wellbeing, opens fair-priced shops carrying daily necessities inside factories, with products offered at a 10% discount to external prices and a points scheme that workers collect for free health-insurance and health services.
- American scale-up, Stony Creek Colors , offers natural indigo sustainable crops to small and mid-size tobacco farmers who are at risk of losing their income due to falling tobacco sales. The cash crop provided by Stony Creek Colors enables the farmers to retain their livelihood.
- Dutch start-up, A Beautiful Mess , runs a creative space to assist refugees in realizing social and economic independence by creating sustainable apparel products.
- U.S.-based start-up company Lab 141 creates small batches of made-to-fit clothing using 3D printing. Through these methods, Lab 141 is promoting and bringing to life the concept of “sizeless” fashion.
- Indian scale-up pajama company Sudara develops professional and sewing skills in women who have escaped from or are at high risk of being sex trafficked.
- Hailing from France, scale-up company Constant & Zoe creates functional and fashionable clothing for men, women and children with disabilities.
The prestigious jurors overseeing the final event include:
- Mr. Tommy Hilfiger
- Ankiti Bose, Co-Founder & CEO, Zilingo
- Noor Tagouri, Journalist, Activist and Speaker
- Daniel Grieder, CEO, Tommy Hilfiger Global and PVH Europe
- Martijn Hagman, CFO, Tommy Hilfiger Global & COO, Tommy Hilfiger Global and PVH Europe
- Willemijn Verloop, Founding Partner, Social Impact Venture
- Steven Serneels, CEO and Board Member, EVPA
- Katrin Ley, Managing Director, Fashion for Good
The jury will award €150,000 between two winners to fund the advancement of their business proposals. The winners will also receive a year-long mentorship with Tommy Hilfiger’s and INSEAD’s global experts, as well as a place in the INSEAD Social Entrepreneurship Program (ISEP). An additional €10,000 will be awarded to the finalist team who wins the “Audience Favorite Vote.”
Tommy Hilfiger’s vision is to create fashion that opens minds and closes loops. Find out more about the brand’s long-term sustainability efforts, particularly in the areas of inclusivity and circularity, at: https://global.tommy.com/en_int/about-us-corporate-sustainability .
Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger, #FashionFrontierChallenge, #MakeNewPossible and @TommyHilfiger.
# # #
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS , Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy .com.
About PVH Corp.
PVH sets the standard of style as one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our iconic portfolio includes TOMMY HILFIGER , CALVIN KLEIN , Van Heusen , IZOD , ARROW , Speedo *, Warner’s , Olga and Geoffrey Beene brands, as well as the digital-centric True & Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 38,000 associates operating in over 40 countries and nearly $9.7 billion in annual revenues. That’s the power of PVH.
*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200112005011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
